Ponaxen (Ponatinib) is a powerful medication designed to treat certain types of blood cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), that have shown resistance to other treatments. Available in both 45mg and 15mg doses, Ponaxen offers patients a cutting-edge approach by targeting abnormal proteins driving cancer growth, helping to control and manage the disease.
Venex 100mg, powered by the active ingredient Venetoclax, is a revolutionary oral treatment for specific blood cancers, including chronic lymphocytic leukaemia (CLL) and Acute Myeloid Leukemia (AML). This advanced medication targets and inhibits the BCL-2 protein, which plays a crucial role in helping cancer cells survive. By blocking this protein, Venex 100mg promotes cancer cell death, offering a highly effective…
